FIRST IL-2 U.S. PATENT ISSUES: ROCHE HAS EXCLUSIVE RIGHTS
FIRST IL-2 U.S. PATENT ISSUES: ROCHE HAS EXCLUSIVE RIGHTS under an agreement with patent holder Ajinomoto. "Roche is not aware of any recombinant interleukin-2 in the clinic that is produced by a method that does not fall within the issued claims," Roche VP and Chief Patent Counsel Jon Saxe commented in an April 19 press release. The patent (No. 4,738,927), Roche said, "covers genetic engineering techniques including novel DNA sequences and organisms containing such DNA." The company is maintaining that it will have the right "in the U.S. and many other countries to exclude others from making, using or selling recombinant human IL-2 produced using such techniques." Immunex, the Seattle-based biotech firm, assisted Roche in the development of IL-2. Under the 1981 research agreement, Immunex conducted preclinical research, with Roche responsible for the molecular development of the lymphokine product. Roche's relationship with Ajinomoto evolved from work by Immunex founders Christopher Henney and Steven Gillis with the Japanese firm prior to the formation of Immunex. "This development is an important one for Immunex," CEO Stephen Duzan commented in a separate, same-day release. "The patent confirms the leadership position of Immunex and Hoffmann-LaRoche in the commercial development of IL-2." The product is currently is clinical development in several U.S. centers for treatment of various types of cancer including malignant melanoma, renal cell cancer and colon cancer. Immunex received payment for early development of the protein, retains the right to manufacture a portion of the IL-2 sold by Roche, and will receive royalties on any worldwide sales. The action by the U.S. Patent & Trademark Office apparently clouds the position of Cetus, whose IL-2 product, Proleukin, is currently in Phase III development in the U.S. and pending approval in certain European countries. Cetus has filed for patents in the U.S., basing its position on muteins, or slightly altered formulations of the natural molecule. Whether Cetus will be excluded from taking its product to market likely will depend on a cross-licensing agreement, such as the one between Schering and Roche covering alpha interferon, or will be settled in court.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: